Related Experiment Videos
Early Remission of Type B Insulin Resistance Syndrome Achieved by Glucocorticoid-based Immunosuppressive Therapy and
Yuki Matsumura-Tojima1, Tomoya Sugita1, Yusuke Tanizaki1
1Department of Diabetes and Endocrinology, Tokushima Red Cross Hospital, Japan.
Abstract:
Type B insulin resistance syndrome (TBIRS) is an extremely rare autoimmune disorder characterized by severe insulin resistance and/or hypoglycemia caused by autoantibodies against the insulin receptor (IRAb). We report the case of a 52-year-old woman who presented with weight loss and severe hyperglycemia resistant to high-dose insulin therapy. Markedly elevated IRAb levels confirmed the diagnosis of TBIRS. Glucocorticoid-based immunosuppressive therapy with cyclosporine rapidly improved glycemic control, and clinical remission was achieved approximately 40 days after treatment initiation. Intermittently scanned continuous glucose monitoring enabled the visualization of the transition from extreme insulin resistance to near-normoglycemia and helped avoid severe hypoglycemia during the patient's antibody decline period.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes II: Pathophysiology
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes III: Clinical Manifestations
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis